Were Harold Ford Jr.’s CME (CME) share acquisitions open-market purchases?

No, the reported acquisitions were not open-market purchases. They were grants of Class A common stock as director compensation, including fully vested equity from the annual program and shares issued in lieu of part of his annual cash retainer.

What price per share was used for Harold Ford Jr.’s CME compensation grants?

Both reported grants used a reference price of $225 per Class A share. For shares issued instead of cash, the number of shares was determined by dividing the annual cash retainer by CME Group’s closing price on the grant date.

Director Harold Ford Jr. receives 1,067 CME Group (CME) shares as equity compensation

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

CME Group Inc. director Harold Eugene Ford Jr. reported receiving equity-based compensation in the form of Class A common stock. On June 25, 2026, he was granted 422 fully vested shares at $225 per share under the CME Group Director Stock Plan, as part of the annual equity compensation program for non-employee directors. On the same date, he also acquired 645 shares issued in lieu of a portion of his annual cash retainer, with the share count determined by dividing the cash retainer by the closing price on the grant date. These are compensation-related share awards, not open-market purchases or sales.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Ford Harold Eugene Jr.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock Class A	645	$225.00	$145K
Grant/Award	Common Stock Class A	422	$225.00	$95K

Holdings After Transaction: Common Stock Class A — 1,736 shares (Direct, null)

Footnotes (1)

Represents a grant of fully vested shares of Class A Common Stock issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. These shares are not subject to any vesting conditions. At the Reporting Person's election, shares issued in lieu of all or a portion of the annual cash retainer for serving as a member of the Board of Directors. The number of shares was determined by dividing the cash retainer by the closing price on the date of grant.

Key Figures

Equity grant 1: 422 shares Equity grant 2: 645 shares Reference price per share: $225.00 per share +3 more

6 metrics

Equity grant 1 422 shares Fully vested Class A shares under annual director equity program on June 25, 2026

Equity grant 2 645 shares Class A shares issued instead of part of annual cash retainer on June 25, 2026

Reference price per share $225.00 per share Price used for both reported Class A stock grants

Total shares granted 1,067 shares Combined total of 422-share and 645-share director compensation awards

Post-grant holding (entry 1) 2,158 shares Total Class A shares shown as held following the 422-share grant entry

Post-grant holding (entry 2) 1,736 shares Total Class A shares shown as held following the 645-share grant entry

Key Terms

annual equity compensation program, CME Group Director Stock Plan, annual cash retainer, closing price on the date of grant

4 terms

annual equity compensation program financial

"Represents a grant of fully vested shares ... as part of the Issuer's annual equity compensation program for non-employee directors"

CME Group Director Stock Plan financial

"issued to the Reporting Person as part of the Issuer's annual equity compensation program ... under the CME Group Director Stock Plan"

annual cash retainer financial

"shares issued in lieu of all or a portion of the annual cash retainer for serving as a member of the Board of Directors"

closing price on the date of grant financial

"The number of shares was determined by dividing the cash retainer by the closing price on the date of grant"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 04:16 PM Accepted by SEC EDGAR 06/29/2026 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ford Harold Eugene Jr.

(Last)

(First)

(Middle)

20 SOUTH WACKER DR.

(Street)

CHICAGO

ILLINOIS

60606

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock Class A	06/25/2026		A⁽¹⁾		645	A	$225	1,736	D
Common Stock Class A	06/25/2026		A⁽²⁾		422	A	$225	2,158	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents a grant of fully vested shares of Class A Common Stock issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. These shares are not subject to any vesting conditions.

2. At the Reporting Person's election, shares issued in lieu of all or a portion of the annual cash retainer for serving as a member of the Board of Directors. The number of shares was determined by dividing the cash retainer by the closing price on the date of grant.

Remarks:

	/s/ Elizabeth Hensen, as Attorney-in-Fact for Harold E. Ford Jr.	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did CME (CME) director Harold Ford Jr. report?

Harold Eugene Ford Jr., a director of CME Group, reported receiving grants of Class A common stock on June 25, 2026. He acquired 422 fully vested shares as annual equity compensation and 645 additional shares issued instead of part of his cash retainer.

How many CME Group Class A shares were granted to Harold Ford Jr.?

He received 422 fully vested Class A shares under the annual equity compensation program and 645 Class A shares in lieu of part of his cash retainer, for a combined total of 1,067 compensation-related shares granted on June 25, 2026.

Are Harold Ford Jr.’s CME equity awards subject to vesting conditions?

The 422-share grant under the CME Group Director Stock Plan is fully vested and not subject to any vesting conditions. The filing does not state additional vesting terms for the 645 shares issued in lieu of cash, beyond describing them as issued for the annual retainer.